Immunic, Inc. (NASDAQ:IMUX) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET
Company Participants
Jessica Breu - Head, Investor Relations and Communications
Daniel Vitt - Chief Executive Officer and President
Glenn Whaley - Chief Financial Officer
Hella Kohlhof - Chief Scientific Officer
Conference Call Participants
Andreas Argyrides - Wedbush
Yasmeen Rahimi - Piper Sandler
Matt Kaplan - Ladenburg
Michael Kratky - SVB Securities
Jessica Breu
Good morning, everybody and welcome to Immunic’s Second Quarter 2022 Earnings Call. My name is Jessica Breu, Head of Investor Relations and Communications at Immunic. I will also be the moderator on today’s call.
Speaking on the call are Dr. Daniel Vitt, our Chief Executive Officer and President as well as Glenn Whaley, our Chief Financial Officer. For the Q&A section of today’s webcast, we also have with us our Chief Scientific Officer, Dr. Hella Kohlhof. [Operator Instructions]
Before we begin, I would like to remind you that this presentation may contain forward-looking statements. Such statements can be identified by words such as may, will, expect, anticipate, estimate or words with similar meaning and such statements involve a number of risks and uncertainties that could cause Immunic’s actual results to differ materially from those discussed here. Please note that these forward-looking statements reflect the Immunic’s opinions only as of the date of this presentation, and it undertakes no obligation to revise or publicly release the result of any revisions to these forward-looking statements in light of new information or future events. Please refer to Immunic’s SEC filings for a more detailed description of the risk factors that may affect Immunic’s results and these forward-looking statements.
I would now like to turn the webcast over to our CEO and President, Dr. Daniel Vitt, to begin the presentation. Daniel, up to you.
Daniel Vitt
Yes. Thank you, Jessica. And I would like to welcome everybody to Immunic’s second quarter 2022 earnings call. Earlier today, we announced our financial results for the quarter and mid-June 30, 2022, and highlighted recent activities as well as upcoming milestones related to our clinical development pipeline.
During today’s call, we will walk through our second quarter 2022 and subsequent highlights, additional clinical updates we provided in the filings this morning, financial and operating results as well as anticipated milestones. As Jessica noted, before we close the call, you will have the opportunity to ask questions.
The second quarter of 2022 was a period of continued progress in our clinical programs, which we believe set the stage for important data readouts during the second half of this year. In particular, we look forward to reporting first clinical activity data for our selective oral IL-17 inhibitor, IMU-935 in psoriasis and first in human healthy-volunteer data from IMU-856 are already available and systemically acting small molecule that has shown preclinical lead to regulate intestinal barrier function and regenerate bowel epithelium.